Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (9582)	11/4/1998 8:50:00 AM
From: xbrent	Read Replies (1) \| Respond to of 25711

Should be a good day in markets overall, could be really big day,week and month. On the day after the election two years ago, the market did very well and kept on doing well. This time the election pretty much assured investors that Bill will not be impeached therefore political stability. Japanese market had big day yesterday, ongoing discussion of lower interest rates in Europe and the US. Looks like a big day to me. I think that the Dow is a little high but many stocks are well under the July high and they have lots of room to run on the upside. For example, Merrill Lynch was $108 in July now MER is $62.

To: Joe Copia who wrote (9582)	11/4/1998 9:27:00 AM
From: MoneyBaggs	Read Replies (1) \| Respond to of 25711

Joe, this is what you are missing on SGNC: News November 4, 06:11 Eastern Time PASADENA, CALIF. (Nov. 4) BUSINESS WIRE -Nov. 4, 1998--Sanguine Corp. (OTC BB: SGNC) Wednesday released findings of a major scientific breakthrough in the development of its synthetic blood substitute, PHER-02. Research scientists in the current program for Sanguine at Battelle Memorial Institute (BMI) have developed five "novel" drug compounds to date that have "camouflage characteristics" which extend the effective life of the compounds in the body and prevent the body from rejecting a synthetic substance. "The great significance of this breakthrough cannot be overstated," commented Sanguine President and Chief Executive Officer Thomas C. Drees, Ph.D. "Prior to this initial finding by Battelle, we already knew about 150 possible end-use applications for PHER-02. This recent research suggests that the number of applications could be greatly expanded. Finally, this breakthrough improves the overall patentability of the product." Battelle's findings address problems found in earlier products as well as those of current competitor products, according to Drees. The limitation of short lifetime within the body would significantly restrict the type of procedures for which a blood substitute could be used. BMI chemists have conceived "novel" compounds that are expected to increase lifetimes in the bloodstream and allow the benefit of prolonged oxygen delivery to the patient. In its report to Sanguine, BMI also states its objective to establish the dates of Battelle's inventions and provide patent protection for the compounds and methodologies prepared and developed for Sanguine. Battelle is the world's largest independent contract research group of scientists, engineers, and other specialists. Its scientists have provided research since 1994 in support of Sanguine's efforts to develop, manufacture and market a proprietary synthetic red blood cell substitute. "Sanguine estimates the annual worldwide market potential for a synthetic red blood cell substitute at $20 billion," stated Drees. "In the United States alone, nearly everyone who reaches the age of seventy-five will need blood, plasma, or one of their components at least once in his lifetime." Drees, who has been in the forefront of the artificial blood products field for more than 20 years, was the president and CEO of the only company to have obtained FDA approval for a synthetic blood product to date. For appropriate risk factors please refer to the 10SB Registration Statement previously filed by the company with the Securities & Exchange Commission at www.sec.gov.